New pain Drug's breast milk safety under the microscope
NCT ID NCT07378865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing how much of the pain medication suzetrigine (JOURNAVX) gets into breast milk after a single dose. Twelve healthy breastfeeding women will provide milk samples to measure the drug and its breakdown product. The goal is to estimate how much a nursing baby might be exposed to, which could guide future use of this drug during breastfeeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
suzetrigine (also known as VX-548, JOURNAVX)
What this could lead to
If it works, this could help determine whether suzetrigine is safe to use while breastfeeding, guiding pain treatment options for nursing mothers.
What could go wrong
This is a very early, small study (12 people) that only measures drug levels in milk, not actual effects on infants. It may not reflect real-world use or long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON - Utah - Salt Lake City Office
RECRUITINGSalt Lake City, Utah, 84124, United States